IP Library Granted Patent US 7,273,920
Granted Patent B2
US 7,273,920 · App. 10/345,281 · Granted Sep 25, 2007

Controlling protein levels in eucaryotic organisms

Assignee: Wellstat BioCatalysis, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,273,920
App. No.
10/345,281
Granted
Sep 25, 2007
Kind
B2
Abstract

The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.

Claims (35)

1. A compound comprising;

a) a ubiquitination recognition element which is able to bind to either the E3 or E2 functional elements of the ubiquitination system, wherein said ubiquitination recognition element has a molecular weight less than 30,000 and has a binding affinity for said E3 and/or E2 elements of the ubiquitination system of at least 10 2 M −1 , and;

a target protein binding element that is able to bind specifically to a target protein wherein said target protein binding element has a molecular weight of less than 30,000 and has a binding affinity for said target protein greater than 10 5 M −1 ,

wherein said ubiquitination recognition element is covalently linked to said target protein binding element.

2. A compound comprising;

a) a ubiquitination recognition peptide element which is able to bind to either the E3 or E2 functional elements of the ubiquitination system, wherein said ubiquitination recognition peptide element has a molecular weight less than 30,000 and has a binding affinity for said E3 and/or E2 elements of the ubiquitination system of at least 10 2 M −1 ,

b) a target protein binding element that is able to bind specifically to a target protein wherein said target protein binding element has a molecular weight of less than 30,000 and has a binding affinity for said target protein greater than 10 5 M −1 ,

wherein said ubiquitination recognition peptide element is covalently linked to said target protein binding element.

3. A compound comprising;

a) a ubiquitination recognition element which is able to bind to either the E3 or E2 functional elements of the ubiquitination system, wherein said ubiquitination recognition element has a molecular weight less than 30,000 and has a binding affinity for said E3 and/or E2 elements of the ubiquitination system of at least 10 2 M −1 and;

b) a target protein binding peptide element that is able to bind specifically to a target protein wherein said target protein binding peptide element has a molecular weight of less than 30,000 and has a binding affinity for said target protein greater than 10 5 M −1 ,

wherein said ubiquitination recognition element is covalently linked to said target protein binding peptide element.

4. A compound comprising;

a) a ubiquitination recognition peptide element which is able to bind to either the 3 or E2 elements of the ubiquitination system, wherein said ubiquitination recognition peptide element has a molecular weight less than 30,000 and has a binding affinity for said E3 and/or E2 elements of the ubiquitination system of at least 10 2 M −1 and;

b) a target protein binding peptide element that is able to bind specifically to a target protein

wherein said target protein binding peptide element has a molecular weight of less than 30,000 and has a binding affinity for said target protein greater than 10 5 M −1 wherein said ubiquitination recognition peptide element is covalently linked to said target protein binding peptide element.

5. A compound as in claim 1 wherein said ubiquitination recognition element has an affinity of at least 10 3 M −1 and a molecular weight between 50 and 10,000.

6. A compound as in claim 5 wherein said target protein binding element has a molecular weight from 50 to 10,000 and a binding affinity of greater than 10 6 M −1 .

7. A compound as in claim 1 wherein said ubiquitination recognition element has an affinity of at least 10 4 M −1 and a molecular weight between 50 and 3,000.

8. A compound as in claim 1 wherein said target protein binding element has a molecular weight from 50 to 3,000 and a binding affinity of greater than 10 7 M −1 .

9. A compound as in claim 5 wherein said target protein binding element has a molecular weight from 50 to 3,000 and a binding affinity of greater than 10 8 M −1 .

10. A compound as in claim 1 wherein said ubiquitination recognition element contains an amino acid with a free amino terminal selected from the group consisting of Phe, Arg, Lys, Trp, Leu, Asn, Asp, Gln, Tyr, His, Glu, Cys, Thr, Ser and Ala and oxidized derivatives thereof.

11. A compound as in claim 1 wherein said ubiquitination recognition element contains an amino acid selected form the group consisting of Phe, Arg, Lys, Asn, Asp, Gln, Glu and Cys.

12. A compound as in claim 1 wherein said ubiquitination recognition element contains an amino acid selected from the group consisting of Arg, Phe, Asp, Gln and Glu.

13. A compound as in claim 1 wherein said ubiquitination recognition element contains a moiety selected from the group consisting of Arg-εAhx-Cys, Arg-β-Ala-εAhx-Cys, Arg-εAhx-εAhx-Cys, Phe-εAhx-Cys, Phe-β-Ala-εAhx-Cys, Phe-εAhx-εAhx-Cys, Arg-Ala-εAhx-Cys, Arg-Ala-β-Ala-εAhx-Cys (SEQ ID NO:66), Arg-Ala-εAhx-εAhx-Cys, Phe-Ala-εAhx-Cys, Phe-Ala-β-Ala-εAhx-Cys (SEQ ID NO:67) and Phe-Ala-εAhx-εAhx-Cys.

14. A compound as in claim 1 wherein said ubiquitination recognition element contains a moiety selected from the group consisting of; Arg-εAhx-Cys, Arg-β-Ala-εAhx-Cys, Arg-εAhx-εAhx-Cys, Phe-εAhx-Cys, Phe-β-Ala-εAhx-Cys, Phe-εAhx-εAhx-Cys.

15. A compound as in claim 1 wherein said recognition element contains a moiety selected from the group consisting of Phe-εAhx-Cys, Phe-β-Ala-εAhx-Cys, Phe-εAhx-εAhx-Cys.

16. A compound as in claim 1 wherein said ubiquitination recognition element is a compound able to inhibit a ubiquitination reaction by binding to a recognition site of a ubiquitination system.

17. A compound as in claim 1 wherein said ubiquitination recognition element is a compound able to interact with the recognition site of the ubiquitination system, said recognition sites selected from the recognition sites for a ubiquitination recognition signal selected from the group consisting of N-end N-recognin, ‘destruction box’ or D box, PEST motifs, Deg1, Deg2, delta (δ) domains, WW domain binding peptides and phosphorylated sequences.

18. A compound as in claim 17 wherein said ubiquitination recognition element is a compound able to inhibit a ubiquitination reaction by binding to the recognition site of the ubiquitination system, said recognition sites selected from the recognition sites for a ubiquitination recognition signal selected from the group consisting of N-end N-recognin, ‘destruction box’ or D box, phosphorylated sequences.

19. A compound as in claim 1 wherein the ubiquitination recognition element is a compound able to inhibit a ubiquitination reaction by binding to the recognition site of the ubiquitination system, wherein said ubiquitination system is the N-end rule ubiquitination system.

20. A compound as in claim 1 wherein said degradation results in altered presentation of degradation products on MHC proteins.

21. A compound as in claim 20 wherein said MHC proteins are selected from MCH class I and MCH class II.

22. A compound as in claim 1 wherein said compound has a molecular weight of less than 3,000.

23. A compound as in clam 1 wherein said ubiquitination recognition element binds the same ubiquitination recognition site as an N-recognin or its equivalent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2007
From: PROTEINIX CORPORATION
To: WELLSTAT BIOCATALYSIS, LLC
Reel/Frame 019735/0264 →
Continuity (3)
Division 0988013200 · Jun 14, 2001
Division 0940678100 · Sep 28, 1999
Related Publication 20030153727A1 · Aug 14, 2003